Journal
JACC-CARDIOVASCULAR INTERVENTIONS
Volume 3, Issue 3, Pages 265-275Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2009.12.013
Keywords
myocardial regeneration; stem cells; training; injection; catheter
Categories
Funding
- Cardiovascular Biotherapeutics
- Angioblast Systems, Inc.
- Biologics Delivery Systems, Inc. (Cordis Corporation)
- Cardio3 Biosciences
- CardioPolymers Inc.
- Medtronic, Inc.
- Ablation Frontiers Inc.
- Astra-Zeneca Inc.
- Sanofi Aventis Inc.
- Magnetecs Inc.
- Bard Inc.
- Bioheart Inc.
- Lantheus
- Acusphere
- CV Therapeutics
- Philips Medical Systems
- General Electric Medical Systems
- Thoratec Corp
- Cordis Corporation
- Abbott Vascular
- Boston Scientific
- Cordis
- ev3
- [NIH-R01HL081715A1]
- [NIH-1R21DK078029-01]
- British Heart Foundation [RG/10/11/28457] Funding Source: researchfish
Ask authors/readers for more resources
The field of myocardial regeneration (angiogenesis and myogenesis) might prove to play an important role in the future management of cardiovascular disease. Stem cells are currently undergoing testing in Phase I and Phase II clinical trials. Methods of delivery will affect the outcome of such therapies, perhaps significantly. This document provides suggested guidance in 4 methods of delivery: endocardial, intracoronary, coronary sinus, and epicardial. (J Am Coll Cardiol Inty 2010;3:265-75) (C) 2010 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
